Skip to main content

Amyloidosis; Systemic

4
Pipeline Programs
2
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 3 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Attralus
AttralusFL - Naples
3 programs
2
1
AT02Phase 21 trial
124I-AT03Phase 11 trial
AT-02Phase 11 trial
Active Trials
NCT05201911Completed13Est. Sep 2022
NCT05521022Unknown100Est. Mar 2025
NCT05951049Recruiting120Est. Feb 2026
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
1
DaratumumabPhase 2Monoclonal Antibody1 trial
DoxycyclineN/ASmall Molecule1 trial
Active Trials
NCT03401372Completed140Est. Dec 2020
NCT04474938Unknown40Est. Mar 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AttralusAT02
UNION therapeuticsDaratumumab
AttralusAT-02
Attralus124I-AT03
UNION therapeuticsDoxycycline

Clinical Trials (5)

Total enrollment: 413 patients across 5 trials

NCT05951049AttralusAT02

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Start: Sep 2023Est. completion: Feb 2026120 patients
Phase 2Recruiting
NCT04474938UNION therapeuticsDaratumumab

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Start: May 2021Est. completion: Mar 202440 patients
Phase 2Unknown
NCT05521022AttralusAT-02

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Start: Sep 2022Est. completion: Mar 2025100 patients
Phase 1Unknown
NCT05201911Attralus124I-AT03

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

Start: Nov 2021Est. completion: Sep 202213 patients
Phase 1Completed
NCT03401372UNION therapeuticsDoxycycline

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

Start: Apr 2018Est. completion: Dec 2020140 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 413 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.